These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP. Leontyev D; Katsman Y; Branch DR Blood; 2012 May; 119(22):5261-4. PubMed ID: 22508937 [TBL] [Abstract][Full Text] [Related]
3. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455 [TBL] [Abstract][Full Text] [Related]
4. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Crow AR; Song S; Suppa SJ; Ma S; Reilly MP; Andre P; McKenzie SE; Lazarus AH Blood; 2011 Jan; 117(3):971-4. PubMed ID: 21045192 [TBL] [Abstract][Full Text] [Related]
5. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295 [TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. Yu X; Menard M; Seabright G; Crispin M; Lazarus AH Transfusion; 2015 Jun; 55(6 Pt 2):1501-11. PubMed ID: 25752470 [TBL] [Abstract][Full Text] [Related]
7. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway. Crow AR; Yu H; Han D; Lazarus AH PLoS One; 2013; 8(8):e71882. PubMed ID: 23940791 [TBL] [Abstract][Full Text] [Related]
8. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Crow AR; Song S; Freedman J; Helgason CD; Humphries RK; Siminovitch KA; Lazarus AH Blood; 2003 Jul; 102(2):558-60. PubMed ID: 12649142 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Song S; Crow AR; Siragam V; Freedman J; Lazarus AH Blood; 2005 Feb; 105(4):1546-8. PubMed ID: 15479722 [TBL] [Abstract][Full Text] [Related]
10. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Crow AR; Suppa SJ; Chen X; Mott PJ; Lazarus AH Blood; 2011 Dec; 118(24):6403-6. PubMed ID: 22001393 [TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia. Tremblay T; Paré I; Bazin R Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706 [TBL] [Abstract][Full Text] [Related]
12. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Song S; Crow AR; Freedman J; Lazarus AH Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Crow AR; Song S; Siragam V; Lazarus AH Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274 [TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Siragam V; Crow AR; Brinc D; Song S; Freedman J; Lazarus AH Nat Med; 2006 Jun; 12(6):688-92. PubMed ID: 16715090 [TBL] [Abstract][Full Text] [Related]
15. GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out. Lewis BJB; Leontyev D; Neschadim A; Blacquiere M; Branch DR Clin Exp Immunol; 2018 Sep; 193(3):293-301. PubMed ID: 29704458 [TBL] [Abstract][Full Text] [Related]
16. Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain. Leontyev D; Neschadim A; Branch DR Transfusion; 2014 Nov; 54(11):2871-9. PubMed ID: 24826802 [TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Samuelsson A; Towers TL; Ravetch JV Science; 2001 Jan; 291(5503):484-6. PubMed ID: 11161202 [TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition. Norris PAA; Kaur G; Khan R; Zhu G; Ni H; Lazarus AH Blood; 2021 Apr; 137(15):2114-2124. PubMed ID: 33662988 [TBL] [Abstract][Full Text] [Related]
19. Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating Fcγ receptors. Nishimoto T; Okazaki Y; Numajiri M; Kuwana M Int J Hematol; 2017 May; 105(5):598-605. PubMed ID: 28028748 [TBL] [Abstract][Full Text] [Related]
20. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Katsman Y; Foo AH; Leontyev D; Branch DR Transfusion; 2010 Jun; 50(6):1285-94. PubMed ID: 20088841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]